Sugi Predict

Sugi Predict / Compounds / SCHEMBL2407930

SCHEMBL2407930

SCHEMBL2407930

CC(C)(C)[Si](C)(C)Oc1ccc2c(C(=O)c3ccc(OCCN4CCCCC4)cc3)c(-c3ccc(O)cc3)sc2c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 20/20 0.77
▸ ESR2 Q92731 19/20 0.77
▸ MEN1 O00255 2/20 0.77
▸ ALDH1A1 P00352 2/20 0.77
▸ LMNA P02545 2/20 0.77
▸ TP53 P04637 2/20 0.77
▸ CYP3A4 P08684 2/20 0.77
▸ MAPT P10636 2/20 0.77
▸ ALOX15 P16050 2/20 0.77
▸ KMT2A Q03164 2/20 0.77
▸ HSD17B10 Q99714 2/20 0.77
▸ TDP1 Q9NUW8 2/20 0.77
▸ PLD2 O14939 1/20 0.77
▸ KDM1A O60341 1/20 0.77
▸ NR1I2 O75469 1/20 0.77
▸ USP2 O75604 1/20 0.77
▸ C5 P01031 1/20 0.77
▸ FYN P06241 1/20 0.77
▸ PGR P06401 1/20 0.77
▸ ADRA2A P08913 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29627141 1.00 ESR1 (0.77) ESR1ESR2MEN1ALDH1A1LMNA
SCHEMBL2404570 0.95 ESR1 (0.79) ESR1ESR2MEN1ALDH1A1LMNA
SCHEMBL12269725 0.91 ESR1 (0.67) ESR1ESR2MEN1ALDH1A1LMNA
SCHEMBL5686648 0.88 ENPP3 (0.69) ESR1ESR2MEN1ALDH1A1LMNA
SCHEMBL11184659 0.88 ESR1 (0.81) ESR1ESR2MEN1ALDH1A1LMNA
SCHEMBL6142097 0.88 ESR1 (0.71) ESR1ESR2MEN1ALDH1A1LMNA
SCHEMBL7621958 0.87 ESR1 (1.00) ESR1ESR2MEN1ALDH1A1LMNA
SCHEMBL11549615 0.87 ESR1 (1.00) ESR1ESR2MEN1ALDH1A1LMNA
SCHEMBL11550698 0.87 ESR1 (1.00) ESR1ESR2MEN1ALDH1A1LMNA
Raloxifene SCHEMBL3162158 0.87 ESR1 (1.00) ESR1ESR2MEN1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220211664-A1 LYMPH DIRECTING PRODRUGS MONASH UNIVERSITY (AU) 2022-07-07 — — US disclosed
US-11311512-B2 Lymph directing prodrugs MONASH UNIVERSITY (AU) 2022-04-26 — — US disclosed
US-20190105299-A1 LYMPH DIRECTING PRODRUGS MONASH UNIVERSITY (AU) 2019-04-11 — — US disclosed
US-20170326103-A1 LYMPH DIRECTING PRODRUGS MONASH UNIVERSITY (AU) 2017-11-16 — — US disclosed
US-20110212958-A1 FATTY ACID RALOXIFENE DERIVATIVES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. (US) 2011-09-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220211664-A1 LYMPH DIRECTING PRODRUGS LTA, ABCB11, LYN ESR1 1606/4885ESR2 2645/4885MEN1 2306/4885
US-11311512-B2 Lymph directing prodrugs LTA, ABCB11, LYN ESR1 1606/4885ESR2 2645/4885MEN1 2306/4885
US-20110212958-A1 FATTY ACID RALOXIFENE DERIVATIVES AND THEIR USES ELOVL5, ELOVL3, ELOVL6 ESR1 7/4885ESR2 5/4885MEN1 2409/4885
US-20190105299-A1 LYMPH DIRECTING PRODRUGS LTA, ABCB11, LYN ESR1 1606/4885ESR2 2645/4885MEN1 2306/4885
US-20170326103-A1 LYMPH DIRECTING PRODRUGS LTA, ABCB11, LYN ESR1 1606/4885ESR2 2645/4885MEN1 2306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.